Shenzhen Kangtai Biological Products Investor Relations

Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company’s marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, adsorbed, rabies vaccine (human diploid cell) for human use, hib conjugate vaccine, measles and rubella combined vaccine, sars-cov-2 vaccine, inactivated, and covid-19 vaccine. Its research and development vaccines comprise measles, mumps and rubella vaccine, 2DTAP- HIB-IPV, 4-valent influenza (split), poliomyelitis vaccine (vero cells), and inactivated, sabin strain. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.

Read Less